Topical Lopinavir Composition for Acyclovir-Resistant HSV
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Herpes Simplex Virus (HSV) infections, such as those caused by HSV1 and HSV2, are inadequate, with nucleoside analogues like acyclovir and penciclovir showing limited efficacy and increasing resistance, particularly in immune-compromised individuals, and existing protease inhibitors like lopinavir and ritonavir are believed to be ineffective against HSV.
Innovation Solution
Compositions comprising lopinavir alone or in combination with ritonavir, formulated for topical application, with specific weight ratios of lopinavir:ritonavir between 9:1 and 18:1, particularly 12:1, are effective in treating and inhibiting HSV infections, including acyclovir-resistant strains, by reducing viral replication and preventing lesion progression.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If nucleoside analogues like acyclovir and penciclovir are used to treat HSV infections, then viral replication is inhibited, but treatment efficacy is limited and resistance develops particularly in immune-compromised individuals
Solution Approach 1:
The patent changes the chemical parameter from nucleoside analogues to protease inhibitors (lopinavir and ritonavir), which have a different mechanism of action targeting the viral protease enzyme. This parameter change resolves the contradiction by providing effective treatment without the resistance issues associated with nucleoside analogues, as demonstrated by the compound's ability to treat acyclovir-resistant strains
2Reliability
If existing protease inhibitors like lopinavir and ritonavir are used, then they are believed to be ineffective against HSV, but the invention discovers they effectively reduce viral replication
Solution Approach 1:
The patent inverts the conventional understanding by demonstrating that protease inhibitors, previously thought to be ineffective against HSV, are actually highly effective. This inversion resolves the contradiction by correcting the misinformation and establishing the true efficacy of lopinavir and ritonavir against HSV infections
3Reliability
If lopinavir and ritonavir are combined in specific weight ratios, then treatment effectiveness is optimized, but formulation complexity increases
Solution Approach 1:
The patent optimizes the weight ratio parameter of lopinavir to ritonavir (specifically 9:1 to 18:1, particularly 12:1) to achieve maximum treatment effectiveness. This parameter optimization resolves the contradiction by providing a clear, defined ratio that simplifies formulation while maximizing therapeutic benefit
Data Source
AI summary
Provided herein are methods and compositions for treating and/or inhibiting the development or progression of conditions caused by, or associated with, Herpes Simplex Virus (HSV) infection. In particular, provided are compositions comprising lopinavir alone, or lopinavir and ritonavir; methods for their manufacture; and the use of said pharmaceutical compositions as a medicament. In particular, pharmaceutical compositions are provided for use in treating and/or inhibiting the progression of HSV related conditions.